BR112019007856A2 - composição, e, método para remover anticorpos de tirosina sulfatada ou fragmentos de ligação a antígeno dos mesmos. - Google Patents

composição, e, método para remover anticorpos de tirosina sulfatada ou fragmentos de ligação a antígeno dos mesmos.

Info

Publication number
BR112019007856A2
BR112019007856A2 BR112019007856A BR112019007856A BR112019007856A2 BR 112019007856 A2 BR112019007856 A2 BR 112019007856A2 BR 112019007856 A BR112019007856 A BR 112019007856A BR 112019007856 A BR112019007856 A BR 112019007856A BR 112019007856 A2 BR112019007856 A2 BR 112019007856A2
Authority
BR
Brazil
Prior art keywords
antigen binding
binding fragments
composition
sulfated tyrosine
tyrosine antibodies
Prior art date
Application number
BR112019007856A
Other languages
English (en)
Other versions
BR112019007856A8 (pt
Inventor
Zhao Jia
RIOS Sandra
Dukleska Schussler Svetlana
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of BR112019007856A2 publication Critical patent/BR112019007856A2/pt
Publication of BR112019007856A8 publication Critical patent/BR112019007856A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J47/00—Ion-exchange processes in general; Apparatus therefor
    • B01J47/02—Column or bed processes
    • B01J47/026—Column or bed processes using columns or beds of different ion exchange materials in series
    • B01J47/028—Column or bed processes using columns or beds of different ion exchange materials in series with alternately arranged cationic and anionic exchangers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

a presente invenção refere-se a composições de anticorpos purificados e de fragmentos de ligação a antígeno faltando tirosina sulfatada sobre um ou mais resíduos tirosina nas cadeias de imunoglobulina. os métodos de purificação para remover variantes de tirosina sulfatada a partir das composições de anticorpos e de fragmentos de ligação a antígeno são também providos.
BR112019007856A 2016-10-28 2017-10-26 Composição, e, método para remover anticorpos de tirosina sulfatada ou fragmentos de ligação a antígeno dos mesmos BR112019007856A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662414209P 2016-10-28 2016-10-28
PCT/US2017/058386 WO2018081329A1 (en) 2016-10-28 2017-10-26 Purification process for removal of tyrosine sulfation antibody variants; purified compositions

Publications (2)

Publication Number Publication Date
BR112019007856A2 true BR112019007856A2 (pt) 2019-10-01
BR112019007856A8 BR112019007856A8 (pt) 2023-04-11

Family

ID=62024014

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019007856A BR112019007856A8 (pt) 2016-10-28 2017-10-26 Composição, e, método para remover anticorpos de tirosina sulfatada ou fragmentos de ligação a antígeno dos mesmos

Country Status (10)

Country Link
US (1) US20200123251A1 (pt)
EP (1) EP3532046A4 (pt)
JP (2) JP7229157B2 (pt)
KR (1) KR102617873B1 (pt)
CN (1) CN109963560A (pt)
AU (1) AU2017347809A1 (pt)
BR (1) BR112019007856A8 (pt)
CA (1) CA3039667A1 (pt)
MX (1) MX2019004957A (pt)
WO (1) WO2018081329A1 (pt)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1268514T3 (da) * 2000-03-27 2006-10-09 Genetics Inst Llc Fremgangsmåde til oprensning af særdeles anioniske proteiner
US7488481B2 (en) * 2003-02-10 2009-02-10 The Brigham And Women's Hospital, Inc. Polypeptides derived from anti-HIV-1 gp120 antibodies that abrogate gp120 binding to CCR5
WO2007067983A2 (en) * 2005-12-09 2007-06-14 Wyeth Sulfotyrosine specific antibodies and uses therefor
CA2887684A1 (en) 2012-10-30 2014-05-08 Peter Becker Purification of polypeptides using dual stage tangential-flow ultrafiltration
TWI596107B (zh) 2013-06-25 2017-08-21 卡地拉保健有限公司 單株抗體之新穎純化方法
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
EP3247718B1 (en) 2015-01-21 2021-09-01 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
WO2021021767A1 (en) * 2019-07-30 2021-02-04 Merck Sharp & Dohme Corp. Anti-pd-1/lag3/tigit trispecific antibodies and anti-pd-1/lag3 bispecific antibodies

Also Published As

Publication number Publication date
JP2019535676A (ja) 2019-12-12
CN109963560A (zh) 2019-07-02
BR112019007856A8 (pt) 2023-04-11
KR102617873B1 (ko) 2023-12-22
KR20190067898A (ko) 2019-06-17
WO2018081329A1 (en) 2018-05-03
AU2017347809A1 (en) 2019-05-09
RU2019116216A3 (pt) 2021-04-28
CA3039667A1 (en) 2018-05-03
RU2019116216A (ru) 2020-11-30
EP3532046A1 (en) 2019-09-04
JP7229157B2 (ja) 2023-02-27
EP3532046A4 (en) 2020-12-30
US20200123251A1 (en) 2020-04-23
JP2023011753A (ja) 2023-01-24
MX2019004957A (es) 2019-06-24

Similar Documents

Publication Publication Date Title
BR112019000970A2 (pt) proteínas de ligação ao antígeno multiespecíficas e métodos de uso das mesmas
EA201990243A1 (ru) Новые антитела, которые специфически связываются с эпитопами вируса зика, и их применения
BR112018003326A2 (pt) anticorpos de ligação de linfopoietina estromal tímica (tslp) e métodos de uso dos anticorpos
CU20170169A7 (es) Anticuerpos de factor xi
BR112018071276A2 (pt) anticorpos anti-il-33, composições, métodos e usos dos mesmos
MX2022012089A (es) Anticuerpos que comprenden un dominio de union al antigeno dependiente de la concentracion ionica, variantes de la region fc, anticuerpos de union a interleucina 8 (il-8) y usos de los mismos.
PE20150023A1 (es) Proteinas de union a antigeno st2
EA201890655A1 (ru) Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
BR112015014751A2 (pt) anticorpos anti-tau humanos
AR087601A1 (es) Anticuerpos sin fc que comprenden dos fragmentos fab y metodos de utilizacion
BR112016013347A2 (pt) anticorpo monoclonal humano neutralizante anti-il-33
BR112018012344A2 (pt) anticorpos que se ligam especificamente a hla-dr e seus usos
PE20180481A1 (es) Anticuerpos de union a tau
EP3255063A3 (en) Antibodies to matrix metalloproteinase 9
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
BR112018007318A2 (pt) anticorpo isolado ou fragmento de ligação a antígeno, composição farmacêutica, e, métodos para tratar uma doença ou condição.
EA201491214A1 (ru) Композиции и способы применения антител, нацеленных на фактор p
EA202090559A1 (ru) Мультиспецифические антитела, специфичные в отношении эпитопов вируса зика, и их применение
PH12014501931A1 (en) Antibodies to matrix metalloproteinase 9
EA201792220A1 (ru) Опосредуемая антителом нейтрализация вируса чикунгунья
PH12021550521A1 (en) Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
BR112017007877A2 (pt) anticorpo ou fragmento do mesmo, epítopo em ccr6 humana solúvel, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo ou fragmento do mesmo, composição e imunoconjugado
EA201792561A1 (ru) Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения
BR112016018082A2 (pt) ?anticorpos úteis na imunização passiva de influenza e composições, combinações e métodos para uso dos mesmos?
KR20220016865A9 (ko) 항원 결합 분자, 약학 조성물, 및 방법

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25A Requested transfer of rights approved

Owner name: MERCK SHARP AND DOHME LLC (US)